Ibrutinib Capsules
Ibrutinib capsules for mantle cell lymphoma and chronic lymphocytic leukaemia. A targeted cancer medicine that blocks a specific protein driving the cancer.
- Category
- Oncology Support
- Active ingredient
- Ibrutinib
- Route
- Oral use
- Form
- Film-coated tablet; Capsule, hard
- Strengths
- 140mg
The exact manufacturer offered is confirmed by the fulfilment partner before supply.
Prescription and consultation requirements for Ibrutinib Capsules vary by destination and are determined by the fulfilment partner.
Ibrutinib Capsules details
- Alternative names
- Imbruvica
- Therapeutic class
- Protein kinase inhibitors; Bruton's tyrosine kinase inhibitors
- Pharmacological class
- Bruton's tyrosine kinase inhibitor
- Dosage forms
- Film-coated tablet; Capsule, hard
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Storage instructions
- Store below 25°C. Keep in the original package to protect from moisture.
Known off-label uses
primary central nervous system lymphoma; diffuse large b-cell lymphoma with certain molecular subtypes; chronic graft-versus-host disease
Contraindications
hypersensitivity to ibrutinib or any excipient; co-administration with st. john's wort
Precautions and warnings
bleeding events including intracranial and gastrointestinal haemorrhage; cardiac arrhythmias including atrial fibrillation and atrial flutter; cardiac failure including fatal cases; hypertension; tumour lysis syndrome; infections including progressive multifocal leukoencephalopathy; cytopenias including neutropenia and thrombocytopenia; interstitial lung disease; hepatitis b reactivation; risk of second primary malignancies including non-melanoma skin cancer; dose reduction required with moderate and strong cyp3a4 inhibitors; avoid use with strong cyp3a4 inducers; caution in patients with severe hepatic impairment; caution in patients with severe renal impairment; splenic rupture reported
Minor side effects
diarrhoea; nausea; vomiting; constipation; stomatitis; fatigue; pyrexia; peripheral oedema; upper respiratory tract infection; pneumonia; sinusitis; urinary tract infection; skin infections; rash; pruritus; bruising; arthralgia; myalgia; muscle spasms; headache; dizziness; dyspnoea; cough; epistaxis; hypertension; decreased appetite; anxiety; insomnia
Moderate side effects
atrial fibrillation; atrial flutter; cardiac failure; hypertension; severe bleeding; intracranial haemorrhage; gastrointestinal haemorrhage; tumour lysis syndrome; interstitial lung disease; pneumonia; sepsis; progressive multifocal leukoencephalopathy; hepatitis b reactivation; second primary malignancy; splenic rupture; ventricular tachyarrhythmia; sudden cardiac death; hepatic failure
Serious side effects
severe bleeding including intracranial haemorrhage, requires immediate medical attention; signs of cardiac failure including shortness of breath, swelling of ankles and feet, rapid weight gain, requires immediate medical attention; signs of atrial fibrillation including palpitations, chest pain, dizziness, fainting, requires immediate medical attention; signs of progressive multifocal leukoencephalopathy including confusion, vision changes, weakness on one side of the body, requires immediate medical attention; signs of tumour lysis syndrome including muscle cramps, irregular heartbeat, decreased urination, requires immediate medical attention; signs of severe infection including high fever, chills, severe cough, requires immediate medical attention; signs of interstitial lung disease including persistent cough, difficulty breathing, chest pain, requires immediate medical attention
Patient summary
Ibrutinib capsules for mantle cell lymphoma and chronic lymphocytic leukaemia. A targeted cancer medicine that blocks a specific protein driving the cancer.
Mechanism of action
Ibrutinib is a targeted cancer medicine that works by blocking a specific protein called Bruton's tyrosine kinase, or BTK. BTK sends signals that tell certain white blood cells called B-cells to grow and divide uncontrollably in cancers like mantle cell lymphoma, chronic lymphocytic leukaemia, and Waldenström's macroglobulinaemia. By blocking BTK, ibrutinib helps stop the cancer cells from growing and dividing, causing them to die. The medicine is taken by mouth in capsule or tablet form.
Drug interactions
warfarin; apixaban; rivaroxaban; dabigatran; heparin; clopidogrel; ketoconazole; itraconazole; voriconazole; posaconazole; clarithromycin; telithromycin; ritonavir; indinavir; nelfinavir; saquinavir; erythromycin; diltiazem; verapamil; fluconazole; rifampicin; carbamazepine; phenytoin; st. john's wort; ciclosporin; tacrolimus; sulfamethoxazole with trimethoprim; grapefruit juice
Age restrictions
Safety and efficacy in children and adolescents below 18 years have not been established.
Pregnancy and breastfeeding
Pregnancy: Ibrutinib should not be used during pregnancy unless clearly necessary. Women of childbearing potential must use effective contraception during treatment and for 3 months after the last dose. Breastfeeding: Should be discontinued during therapy.
What you will receive
Ibrutinib Capsules is a generic medicine sold under the name of its active ingredient, Ibrutinib, rather than under a brand.
- The fulfilment partner confirms the offered manufacturer and product before supply.
- Check the active ingredient, strength, form and pack shown at checkout before confirming an order.